SCHEMBL14090837

SCHEMBL14090837

CC(=N)NCCC[C@H](NC(=O)c1cccn(Cc2ccccc2)c1=O)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.49
▸ BRD2 P25440 1/20 0.48
▸ BRD3 Q15059 1/20 0.48
▸ BRDT Q58F21 1/20 0.48
▸ MAPT P10636 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CNR1 P21554 3/20 0.44
▸ CNR2 P34972 3/20 0.44
▸ POLB P06746 2/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ PAX8 Q06710 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ C3AR1 Q16581 1/20 0.41
▸ TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14090845 0.91 BRD4 (0.53) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090848 0.90 BRD4 (0.39) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090861 0.89 NPSR1 (0.42) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090883 0.89 BRD4 (0.52) BRD4BRD2BRD3BRDTMAPT
SCHEMBL4986504 0.88 BRD4 (0.58) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090936 0.87 BRD4 (0.50) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090856 0.85 C3AR1 (0.40) BRD4MAPTPOLBRXFP1MEN1
SCHEMBL4989359 0.85 BRD4 (0.54) BRD4BRD2BRD3BRDTMAPT
SCHEMBL14090858 0.85 NPSR1 (0.42) MAPTPOLBMEN1KMT2APAX8
SCHEMBL14090874 0.83 BRD4 (0.48) BRD4BRD2BRD3BRDTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 BRD4 2776/4885BRD2 4008/4885BRD3 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback